numares

Executive Summary

Numares AG, founded in 2008 and headquartered in Regensburg, Germany, is a diagnostics company leveraging artificial intelligence and nuclear magnetic resonance (NMR) spectroscopy to develop advanced metabolomic tests for metabolic and cardiovascular diseases. By analyzing metabolite profiles, the company aims to enable earlier and more precise detection of conditions such as cardiovascular disease, chronic kidney disease, and diabetes. Numares’ proprietary NMR platform offers a high-throughput, reproducible method for measuring multiple biomarkers simultaneously, providing a differentiated approach in the growing precision diagnostics market. The company has not yet disclosed specific funding amounts or commercial product launches, indicating it remains in a development or early-commercialization phase. Given the increasing global burden of chronic diseases and the demand for non-invasive, cost-effective diagnostic tools, Numares is well-positioned to address unmet clinical needs. However, limited public information on regulatory progress, partnerships, and financial status introduces uncertainty regarding near-term revenue generation and competitive positioning.

Upcoming Catalysts (preview)

• Q4 2026Regulatory submission for lead cardiovascular diagnostic test60% success
• Q3 2026Strategic partnership with major diagnostic or pharmaceutical company45% success
• Q2 2026Publication of clinical validation study results for metabolic disease panel70% success